- Oral presentation
- Open Access
Safety of CMR in patients with cardiac implanted electronic devices
© Ibrahim et al. 2016
- Published: 27 January 2016
- Ventricular Tachycardia
- Late Gadolinium Enhancement
- Myocardial Scar
- Specific Absorption Rate
- Implanted Cardiac Defibrillator
CMR has been reported to be safe in patients with cardiac implantable electronic device (CIED), provided a specific protocol is followed. The goal of this study is to examine whether this is true for patients excluded from published protocols, e.g. CIED patients with abandoned leads or pacemaker dependency.
The protocol followed at our institution for MR imaging of CIED patients is as follows: 1) Necessity and absence of an alternative imaging modality; 2) Device-related relative contraindications, including the presence of abandoned leads, pacemaker dependency, and time to lead implant < 6 weeks, with the possibility of the ordering physician to overrule these exclusions. 3) A provider with CIED management expertise assesses the baseline device information, where the device was programmed according to the patient's needs with tachyarrhythmia detection and therapy disabled during the scan. 4) Device reinterrogation and reprogramming after completion of the scan, as well as at 1 week and 3 months after imaging.
In the analyzed cohort of 142 patients, only in one pacemaker dependent patient, the heart rate dropped from 90 to 50 bpm during spinal imaging using a fast spin echo sequence (specific absorption rate (SAR) = 1.89 W/Kg) due to elevated noise rate of the ICD. In this patient, a prior cardiac scan was performed a week earlier where no problem was observed, as the cardiac LGE sequences have low SAR of 0.11 W/Kg. Therefore, with the protocol described in this study, CMR imaging can be safely performed in CIED patients without exposing the patients to risk, despite pacemaker dependency, presence of abandoned leads, and other CIED contraindications. This study recommends that CMR imaging be available to more CIED patients who can benefit from it.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.